Vectura strikes again as Sandoz expands VR315 deal
This article was originally published in Scrip
Executive Summary
Vectura has signed another licensing deal for its mystery respiratory product, VR315 (thought widely to be a generic version of GlaxoSmithKline's Advair (fluticasone plus salmeterol) using Vectura's GyroHaler dry powder inhaler). The news that its European marketing partner Sandoz is to take on rest of world rights comes just days after the UK firm announced it had secured an unnamed partner for US development and commercialisation (scripintelligence.com, 03 August 2011).